Analysis for VTRS

📈 Growth & Financial Trajectory

Over the 8 quarters from 2024-Q2 to 2026-Q2, Viatris' revenue remained around $3.75B, ending essentially flat at about $3.76B. The most notable gap was 2025-Q1 where Net Income swung to a large loss, then episodic profitability followed in late 2024 through 2026, with 2025-Q4 and 2026-Q1 printing positive earnings before a small loss in 2026-Q2. Net income moved from -$360.6M in 2024-Q2 to positive in several quarters (e.g., 2024-Q3 +$94.8M), then a trough of -$3,042M in 2025-Q1, and finally a positive run of around +$176.4M in 2025-Q4 and 2026-Q1 before -$118.8M in 2026-Q2.

💰 Margins & Cash Flow

Gross margins have been healthy, generally in the 32-39% range, with operating margins often in positive territory (roughly 4-6%) but punctuated by negative quarters (e.g., 2025-Q4). Net cash flow from operating activities was strong in several quarters (e.g., 2026-Q1: $388.3M, 2026-Q2: $381.8M continuing), while total net cash flow for 2026-Q2 was negative due to large financing/investing outflows.

🛡️ Balance Sheet & Liquidity

Assets run in the mid-to-high $30B range with equity typically around $15-16B and current liabilities around $6-7B. Leverage is moderate; current ratios hover near 1.4-1.6x, and noncurrent liabilities are substantial but manageable given cash generation.

⚠️ Key Drivers & Risks

• Drivers: Global demand for generics/pharma products; steady operating cash flow supports liquidity.
• Risks: Earnings volatility from quarterly swings and one-time tax effects; intense competition in generics and regulatory pricing pressure.